Corbus Pharmaceuticals
CRBP
49 hedge funds and large institutions have $110M invested in Corbus Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 9 closing their positions.
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
38% more capital invested
Capital invested by funds: $79.4M → $110M (+$30.5M)
23% more funds holding
Funds holding: 40 → 49 (+9)
0.98% more ownership
Funds ownership: 0% → 0.98% (+0.98%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
68% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $4.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.44M |
| 2 |
Millennium Management
New York
|
+$5.57M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.82M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.52M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$11.1M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$4.75M |
| 3 |
CI
Conning Inc
Hartford,
Connecticut
|
-$2.38M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$1.36M |
| 5 |
Renaissance Technologies
New York
|
-$1.28M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CI
51
Conning Inc
Hartford,
Connecticut
| – | -$2.38M | -11,709 | Closed |
|
|
GTC
52
Ghost Tree Capital
New York
| – | -$1.36M | -6,667 | Closed |
|
|
53
Renaissance Technologies
New York
| – | -$1.28M | -6,307 | Closed |
|
|
ACP
54
Acuta Capital Partners
Redwood City,
California
| – | -$552K | -2,710 | Closed |
|
|
GGHC
55
Gilder Gagnon Howe & Co
New York
| – | -$508K | -2,495 | Closed |
|
|
BFPW
56
BOK Financial Private Wealth
Denver,
Colorado
| – | -$102K | -500 | Closed |
|
57
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$17K | -83 | Closed |
|
58
Bank of America
Charlotte,
North Carolina
| – | -$7K | -33 | Closed |
|
CRBP Hedge Fund Activity: Q4 2016 in Review
49 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2016, worth a combined $110M — up 38% from $79.4M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CRBP positions and 9 closed out — a net gain of 10 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $8.44M. The largest seller was Perceptive Advisors, cutting an estimated $11.1M.
- 49 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2016, up from 40 in Q3 2016.
- Funds reported $110M of Corbus Pharmaceuticals stock for Q4 2016, up 38% quarter-over-quarter.
- 19 funds opened new Corbus Pharmaceuticals positions in Q4 2016 and 9 closed out, a net change of +10 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2016 was Fidelity Investments, an estimated $8.44M added.
- The largest Corbus Pharmaceuticals seller in Q4 2016 was Perceptive Advisors, an estimated $11.1M sold.
Based on aggregated 13F filings for Q4 2016.